首页> 美国卫生研究院文献>Molecules >Combined Ensemble Docking and Machine Learning in Identification of Therapeutic Agents with Potential Inhibitory Effect on Human CES1
【2h】

Combined Ensemble Docking and Machine Learning in Identification of Therapeutic Agents with Potential Inhibitory Effect on Human CES1

机译:集成集成对接和机器学习技术识别对人类CES1具有潜在抑制作用的治疗药物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The human carboxylesterase 1 (CES1), responsible for the biotransformation of many diverse therapeutic agents, may contribute to the occurrence of adverse drug reactions and therapeutic failure through drug interactions. The present study is designed to address the issue of potential drug interactions resulting from the inhibition of CES1. Based on an ensemble of 10 crystal structures complexed with different ligands and a set of 294 known CES1 ligands, we used docking (Autodock Vina) and machine learning methodologies (LDA, QDA and multilayer perceptron), considering the different energy terms from the scoring function to assess the best combination to enable the identification of CES1 inhibitors. The protocol was then applied on a library of 1114 FDA-approved drugs and eight drugs were selected for in vitro CES1 inhibition. An inhibition effect was observed for diltiazem (IC50 = 13.9 µM). Three others drugs (benztropine, iloprost and treprostinil), exhibited a weak CES1 inhibitory effects with IC50 values of 298.2 µM, 366.8 µM and 391.6 µM respectively. In conclusion, the binding site of CES1 is relatively flexible and can adapt its conformation to different types of ligands. Combining ensemble docking and machine learning approaches improves the prediction of CES1 inhibitors compared to a docking study using only one crystal structure.
机译:人羧酸酯酶1(CES1)负责许多不同治疗剂的生物转化,可能通过药物相互作用促进药物不良反应的发生和治疗失败。本研究旨在解决由于抑制CES1而引起的潜在药物相互作用的问题。基于由10个晶体结构与不同配体和一组294个已知CES1配体复合而成的整体,我们使用对接(Autodock Vina)和机器学习方法(LDA,QDA和多层感知器),考虑到评分功能中的不同能量项评估最佳组合以鉴定CES1抑制剂。然后将该方案应用于1114种FDA批准的药物库中,并选择了八种药物进行体外CES1抑制。观察到地尔硫卓具有抑制作用(IC50 = 13.9 µM)。其他三种药物(苯卓平,伊洛前列素和曲前列环素)显示出较弱的CES1抑制作用,IC50值分别为298.2 µM,366.8 µM和391.6 µM。总之,CES1的结合位点相对灵活,可以使其构象适应不同类型的配体。与仅使用一种晶体结构的对接研究相比,将集成对接和机器学习方法相结合可改善CES1抑制剂的预测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号